Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares of the company's stock, valued at approximately $4,814,359.71. This represents a 0.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Jerrell Shelton also recently made the following trade(s):
- On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24.
Cryoport Stock Performance
CYRX stock traded down $0.08 during midday trading on Friday, reaching $5.69. 397,451 shares of the company's stock traded hands, compared to its average volume of 528,421. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 52-week low of $4.58 and a 52-week high of $20.11. The stock has a market cap of $283.99 million, a P/E ratio of -1.68 and a beta of 1.67. The stock's 50-day moving average is $6.81 and its 200 day moving average is $7.38.
Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million during the quarter, compared to analysts' expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter last year, the company earned ($0.29) earnings per share. As a group, analysts anticipate that Cryoport, Inc. will post -0.99 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on CYRX shares. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Cryoport in a research report on Wednesday, March 5th. Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.50.
Read Our Latest Research Report on Cryoport
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in CYRX. Cadian Capital Management LP boosted its stake in shares of Cryoport by 14.1% in the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock worth $38,332,000 after acquiring an additional 609,021 shares during the period. Millennium Management LLC boosted its stake in Cryoport by 11.0% in the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock worth $32,208,000 after purchasing an additional 409,353 shares during the period. Fred Alger Management LLC lifted its holdings in shares of Cryoport by 49.9% in the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company's stock valued at $21,887,000 after acquiring an additional 898,481 shares during the last quarter. Thematics Asset Management increased its stake in Cryoport by 176.2% during the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company's stock worth $13,828,000 after acquiring an additional 1,087,800 shares during the last quarter. Finally, Deutsche Bank AG raised its position in Cryoport by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock valued at $10,870,000 after purchasing an additional 12,864 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Stories
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
